ALK-Abelló A/S
ALK-B
Kedudukan dalam Saham
#2351
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Harga Saham
$37.76
Modal Pasaran
$8.38B
Perubahan (1 hari)
-0.08%
Perubahan (1 tahun)
12.64%
Negara
DK
Perdagangan ALK-Abelló A/S (ALK-B)
Kategori
Healthcare
Nisbah P/B bagi ALK-Abelló A/S (ALK-B)
Nisbah P/B pada October 2026 TTM: 7.22
Menurut laporan kewangan dan harga saham terkini ALK-Abelló A/S, nisbah P/B semasa (TTM) ialah 7.22. Pada akhir 2023, nisbah P/B syarikat ialah 5.03.
Sejarah nisbah P/B untuk ALK-Abelló A/S dari 2004 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 7.22 | 10.28% |
| 2024 | 6.55 | 30.22% |
| 2023 | 5.03 | -5.24% |
| 2022 | 5.31 | -50.88% |
| 2021 | 10.81 | 24.92% |
| 2020 | 8.66 | 54.24% |
| 2019 | 5.61 | 62.86% |
| 2018 | 3.45 | 52.96% |
| 2017 | 2.25 | -28.29% |
| 2016 | 3.14 | -0.35% |
| 2015 | 3.15 | 17.99% |
| 2014 | 2.67 | 1.30% |
| 2013 | 2.64 | 57.44% |
| 2012 | 1.68 | 14.26% |
| 2011 | 1.47 | -7.18% |
| 2010 | 1.58 | -25.13% |
| 2009 | 2.11 | -24.41% |
| 2008 | 2.79 | -8.71% |
| 2007 | 3.06 | -17.15% |
| 2006 | 3.69 | 138.26% |
| 2005 | 1.55 | 0.00% |
| 2004 | 0.00 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.251 | -13.46% |
US
|
|
| 13.2547 | 83.50% |
US
|
|
| 4.208 | -41.74% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -14.41% |
NL
|
